Results: Seventy-four women were treated on each arm and median PFS was 5.4 versus 5.2 months (P = 0.736), for VG and Cap, respectively. Median overall survival was 20.4 months for the VG arm and 22.4 months for the Cap arm (P = 0.319). Overall response rate was 28.4% in the VG arm and 24.3% in the Cap arm (P = 0.576). Both regimens were generally well tolerated. Neutropenia and fatigue were more common with VG arm and hand-foot syndrome with Cap arm.
resistance to anthracyclines and taxanes. Furthermore, chemotherapy regimens that contain anthracyclines and/or taxanes are now often considered as the 'standard' option for adjuvant treatment of early breast cancer [8, 9] especially in women at high risk, thus limiting their use in patients who subsequently develop disease relapse.
Newer cytotoxic agents such as capecitabine, vinorelbine and gemcitabine are available for the treatment of patients with MBC who have been previously treated with anthracyclines and taxanes [10] . Capecitabine is approved as a single agent for patients with MBC who failed anthracycline and taxane treatment [11] . In this setting, capecitabine as single-agent is associated with an overall response rate (ORR) of 20%-26%, a median progression-free survival (PFS) of 3.0-4.6 months and a median overall survival (OS) of 10.4-15.2 months [12] [13] [14] [15] .
In an attempt to improve treatment outcomes, combination regimens have been tested in the context of phase II trials. A phase II study published by Stathopoulos et al. [16] evaluated the combination of vinorelbine/gemcitabine administered every 2 weeks in anthracycline-and taxane-pretreated (in 50% of the patients) patients with MBC and observed encouraging results with an ORR of 54%, a median PFS of 6 months and a median OS of 11.5 months.
Based on these results, the Breast Cancer Group of the Hellenic Oncology Research Group (HORG) initiated a phase III trial to compare single-agent capecitabine versus the vinorelbine/gemcitabine regimen in patients with MBC pretreated with anthracyclines and taxanes.
patients and methods patients
Women with histologically or cytologically confirmed MBC who had previously received treatment with anthracyclines and taxanes in the adjuvant and/or metastatic settings were eligible for the study. Patients with HER2-positive tumors were eligible for the study, given that they had already received trastuzumab in the first-line setting. Additional inclusion criteria were age >18 years, at least one unidimensionally measurable lesion according to the RECIST [17] , an Eastern Cooperative Oncology Group performance status (PS) of zero to two [18] , a life expectancy of >3 months, adequate organ function [serum bilirubin £1.5 times the upper normal limit (UNL); aspartate aminotransferase and alanine aminitransferase £ 2.5 UNL in the absence of liver metastases or £5 UNL in the presence of liver metastases; serum creatinine £ 1.5 UNL; neutrophils ‡ 1.5 · 10 29 /l, and platelets ‡ 100 · 10
29
/l], central nervous system metastases were allowed provided that they had been irradiated and were clinically and radiologically stable, absence of active infection and of history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) or malnutrition (loss of ‡20% of the original body weight). Previous radiotherapy was allowed provided that it was completed at least 2 weeks before enrollment and measurable lesions were outside the radiation fields. All patients gave written informed consent to participate in the study. The trial was approved by the Ethics and Scientific Committees of the participating centers and was conducted according to the Helsinki Declaration and Good Clinical Practice guidelines [19] . 
treatment plan

dose modifications
For the treatment cycles to be administered according to the scheduled timetable, the absolute granulocyte count had to be >1.5 · 10
29
/l and the platelet count >100 · 10
/l while all other nonhematological toxic effects (except alopecia) had to be grade 1 or less [National Cancer InstituteCommon Toxicity Criteria (NCI-CTC) v. 3 .0] [20] . In patients presenting with neutropenia grade 4, febrile neutropenia, thrombocytopenia grade 3-4 or nonhematological toxicity grade 3-4 (except nausea and vomiting), the doses of all drugs were reduced by 20% for all subsequent cycles. In the case of toxicity reoccurrence, a second dose reduction by 20% in the doses of all drugs was done. Patients requiring dose reductions >40% of the protocol dose were taken off study. The use of growth factors [granulocyte colony-stimulating factor and erythropoiesis-stimulating agents] was allowed at the discretion of the treating physician and according to international recommendations [21, 22] .
baseline and follow-up assessments A complete medical history, evaluation of performance status, detailed physical examination and vital signs, 12-lead electrocardiogram, blood tests (complete blood cell count with differential and blood chemistry) and chest X-ray were carried out at baseline and before every cycle. Computed tomography (CT) scans of the chest, abdomen and brain and a whole-body radionuclide bone scan were also included in the baseline evaluation. Baseline evaluation had to be carried out within 2 weeks before therapy initiation. All measurable lesions were identified at baseline and were monitored throughout. Toxicity was also evaluated at every visit and was reported according to NCI-CTC, version 3 [20] .
Tumor assessment for response or progression was carried out every 2 months. Objective tumor responses were evaluated according to RECIST criteria [17] . All CT scans were reviewed by an independent radiologist and all responses had to be confirmed after 4 weeks. Post-study assessments including PS, toxicity evaluation and tumor measurements were carried out after 30 days. Follow-up included physical examination and radiological tumor assessment and was carried out every 2 months until disease progression. Thereafter, patients were contacted every 4 months until death.
statistical analysis
Randomization was done at the HORG headquarters by the use of a faxed form sent to all participating centers. Concealment of allocation sequence was carried out by use of a computer-generated random code. Patients were randomized to a 1 : 1 ratio, to receive either Cap or VG. The randomization to each arm was done by stratification according to PS (0-1 versus 2), age (£65 versus >65 years), menopausal status (pre-versus postmenopausal), and sensitivity or resistance to anthracycline/taxane treatment. Anthracycline and taxane resistance was defined as tumor progression during treatment or within three months of last dose of chemotherapy in case of metastatic disease or recurrence within 12 months in the adjuvant/neoadjuvant setting. All clinical data were centrally collected and analyzed.
The primary end point was PFS; secondary endpoints included ORR, safety profile and OS associated with each regimen. The study was designed to have 80% power (a = 0.05, two-sided log-rank test) to detect an increase in median PFS from 3 months for the single-agent capecitabine arm [12, 13, 15 ] to 5 months for the VG arm [16] at the statistically significant level of 5%. Assuming an enrollment period of 36 months, 72 patients should be enrolled in each arm to achieve the statistical requirements. Analysis was carried out on an intent-to-treat basis. The PFS was measured from study entry until the day of the first evidence of disease progression or death and OS from the date of study entry to death or last contact. The probability of survival was calculated by the method of Kaplan-Meier [23] and tested for differences by using the log-rank test. All tests were two-sided and were considered significant when the resulting P-value was £0.05. Figure 1 . (36.5%) in the Cap arm discontinued treatment because of disease progression, while 4 (5.5%) (neutropenia n = 2, infection n = 1, allergic reaction n = 1) and 5 (6.8%) (neutropenia n = 2, allergic reaction n = 2, hand-foot syndrome n = 1) patients in ach arm, respectively, discontinued treatment due to toxicity.
The percentage of patients who received subsequent-line of treatment on disease progression was 56.8% in VG arm and 47.3% in Cap arm (P = 0.249). Figure 2 . Similarly, no Figure 3 . Exploratory analyses of PFS and OS were also carried out across various subgroups (supplemental Figure S1A and B, available at Annals of Oncology online). The combination treatment did not offer any PFS or OS benefit in any of the subgroups tested. The only exception was patients with hormone receptor-negative tumor who had significantly longer PFS when treated with capecitabine compared with patients treated with VG (supplemental Figure S1A , available at Annals of Oncology online).
ORR was also similar between the two arms ( Table 2) . In an intention-to-treat analysis, the ORR was 28.4% (1 patient (1.4%) with CR and 20 patients (27.0%) with PR; 95% CI 18.11% to 38.65%) in the VG arm and 24.3% [3 patients (4.1%) with CR and 15 patients (20.3%) with PR; 95% CI 15.55% to 34.10%] in the Cap arm (P = 0.576). The median duration of response was 7.3 months (range 2.6-24.6 months) and 10.8 months (range 1.7-27.8 months) in VG and Cap arms, respectively (P = 0.204).
toxicity
Toxicity was assessed in all chemotherapy cycles and in all patients. Chemotherapy was in general well tolerated and grade III/IV toxic effects were relatively infrequent. No toxic deaths were observed. Table 3 summarizes all treatment-related toxic effects. The most frequent grade III/IV hematological toxicity was neutropenia, which occurred in 17 (23.0%) patients in the VG arm and in 3 (4.1%) in the Cap arm (P = 0.001). All resolved uneventfully. In terms of nonhematological toxicity, fatigue (P = 0.034) was more frequent in the VG arm, while hand-foot syndrome in the capecitabine arm (P = 0.001); however, in most patients, these toxic effects were of grade I or/and II.
discussion
To our knowledge, this is the first phase III trial comparing the vinorelbine/gemcitabine doublet with single-agent capecitabine in patients with MBC previously treated with both an anthracycline and a taxane. However, this trial failed to meet its primary end point of demonstrating a significant prolongation of PFS in favor of the combination arm. An overview of randomized phase III trials [24] [25] [26] comparing single-agent treatment versus combination chemotherapy regimens demonstrated that combination treatments were associated with a significant prolongation of PFS and significantly higher ORR compared with single-agent treatments. The reason for this difference between these studies and the current study is not quite clear. We cannot exclude that patients' characteristics, genetic heterogeneity as well as prior treatments and disease sensitivity to chemotherapeutic agents could account for these observations. However, it should be noted that the above-mentioned studies demonstrated a relative increase in median PFS of 50%. If a difference of this magnitude in favor of the VG arm were to exist, this study would not have had the power to detect it. The sample size in this study was calculated assuming a median PFS of 3 months in the control arm (Cap arm), which was the median PFS reported by several phase II trials [12, 13, 15] . Similarly, PFS estimation for the experimental arm (VG arm) was done based on published results of a phase II trial demonstrating a median PFS of 6 months for the VG combination. Despite the small sample size of this study and its inherent limitations, our results showed a median PFS that is not significantly different between the two treatments.
It is noteworthy that in our trial, capecitabine single-agent arm experienced a longer median PFS than expected. However, the results observed in the single-agent capecitabine arm of the current study are remarkably similar to those observed in recent phase III trials of capecitabine versus combination treatment in anthracycline-and taxane-pretreated patients with MBC [25] [26] [27] . Indeed, median PFS in these trials was 4.2 months and ORR 9.1%-28.8%, while the current study reported a median PFS of 5.2 months and an ORR of 24.3%. Similarly, the results in the VG arm were in the same range with previously reported phase III trials. The current study showed a median PFS of 5.4 months and an ORR of 28.4%, while a phase III trial of vinorelbine/ [24] reported a median PFS of 6.0 months and an ORR of 36% in a similarly pretreated patient population. Similarly, subgroup analyses failed to demonstrate any benefit in favor of the combination arm among all subgroups tested. Only patients with hormone receptor-negative primary tumors seemed to have significantly longer PFS with the Cap arm. However, it should be underlined that these analyses were exploratory and not preplanned by study design and therefore no valid conclusion can be drawn due to small sample size.
Hematological toxicity was significantly higher in the combination arm as was fatigue. On the other hand, hand-foot syndrome was higher in the capecitabine arm as expected. However, our study reported lower rates of hand-foot syndrome compared with recent phase III trials [25] [26] [27] .
In conclusion, this trial failed to demonstrate any significant benefit in terms of ORR, PFS and OS in favor of the combination treatment. Given the higher neutropenia and fatigue associated with doublet chemotherapy and the practical advantage of oral treatment in terms of ease of administration, the VG combination cannot be recommended as a preferable treatment option in this population except perhaps in patients where compliance with a daily oral regimen as well as gastrointestinal tolerance issues are significant.
Despite the improvements observed in the treatment of MBC, there are still several unmet needs. Among them is to determine the best way to combine or sequence cytotoxic agents and targeted therapies in order to achieve the maximum clinical benefit and to develop reliable predictive factors which will allow the selection of patients who are most likely to benefit from a particular agent and save others from unnecessary toxicity of ineffective treatments. Many clinical trials are currently evaluating these questions and it is hoped that one or more of these approaches will prove successful and lead to further progress in the treatment of this devastating disease. disclosure
